Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes

Pharmacogenomics

Volumn 15, Issue 6, 2014, Pages 759-774

  Paolini, Paul ^a,b   Pick, Daniel ^c   Lapira, Jennifer ^d   Sannino, Giuseppina ^d,e   Pasqualini, Lorenza ^d,f   Ludka, Colleen ^d   Sprague, L James ^d   Zhang, Xian ^b   Bartolotta, Elesha A ^a   Vazquez Hidalgo, Esteban ^b   Barba, David Torres ^b   Bazan, Carlos ^b   Hardiman, Gary ^b,d,g  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c CLAREMONT GRADUATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

neonatal rat ventricular myocytes; NRVMs; peroxisome; PPAR ; proliferator activated receptor ; rosiglitazone; T2DM; Type 2 diabetes mellitus

Indexed keywords

ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; DIMETHYL SULFOXIDE; MESSENGER RNA;

ANGPTL4 GENE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CPT1A GENE; CYP1B1 GENE; DRUG EFFECT; ECH1 GENE; EX VIVO STUDY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEART DEVELOPMENT; HEART MUSCLE CELL; HMGCS2 GENE; IMMUNE RESPONSE; LONGITUDINAL STUDY; NONHUMAN; NQO1 GENE; ONTOLOGY; RAT; UPREGULATION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; NEWBORN; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; DIMETHYL SULFOXIDE; EXTRACELLULAR MATRIX; GENE EXPRESSION; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84901986395     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.39     Document Type: Article

References (69)

1. Threatt J, Williamson JF, Huynh K, Davis RM. Ocular disease, knowledge and technology applications in patients with diabetes. Am. J. Med. Sci. 345(4), 266-270 (2013).
2. Zhang P, Zhang X, Brown J et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(3), 293-301 (2010).
3. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47(4), 507-514 (1998).
4. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs 65(3), 385-411 (2005).
5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541), 1096-1105 (2006).
6. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11), 1486-1491 (2003).
7. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51(5), 1507-1514 (2002).
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007).
9. Bell DS, Ovalle F. Tissue triglyceride levels in Type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans. Endocrine Pract. 7(2), 135-138 (2001).
10. Ovalle F, Bell D. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocrine Pract. 8(6), 406-410 (2002).
11. Nemoto S, Razeghi P, Ishiyama M, De Freitas G, Taegtmeyer H, Carabello BA. PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am. J. Physiol. Heart Circ. Physiol. 288(1), H77-H82 (2005).
12. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10), 1134-1146 (1999).
13. Home P. Cardiovascular disease and oral agent glucose-lowering therapies in the management of Type 2 diabetes. Diabetes Technol. Ther. 14(Suppl. 1), S33-S42 (2012).
14. Ajjan RA, Grant PJ. The cardiovascular safety of rosiglitazone. Expert Opin. Drug Saf. 7(4), 367-376 (2008).
15. Rosen CJ. Revisiting the rosiglitazone story-lessons learned. N. Engl. J. Med. 363(9), 803-806 (2010).
16. Blind E, Dunder K, De Graeff PA, Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia 54(2), 213-218 (2011).
17. Shah RD, Gonzales F, Golez E et al. The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha-and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Cell. Physiol. Biochem. 15(1-4), 41-50 (2005).
18. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 42(9), 1033-1049 (1999).
19. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev. 20(5), 649-688 (1999).
20. Gilde AJ, van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol. Scand. 178(4), 425-434 (2003).
21. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther. 122(3), 246-263 (2009).
22. von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in Type 2 diabetic patients without overt heart disease. Diabetes Vasc. Dis. Res. 5(4), 310-318 (2008).
23. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 356(24), 2522-2524 (2007).
24. Chlopcikova S, Psotova J, Miketova P. Neonatal rat cardiomyocytes-a model for the study of morphological, biochemical and electrophysiological characteristics of the heart. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 145(2), 49-55 (2001).
25. Wenzel DG, Wheatley JW, Byrd GD. Effects of nicotine on cultured rat heart cells. Toxicol. Appl. Pharmacol. 17(3), 774-785 (1970).
26. Sasik R, Woelk CH, Corbeil J. Microarray truths and consequences. J. Mol. Endocrinol. 33(1), 1-9 (2004).
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. Series B (Methodological) 57(1), 289-300 (1995).
28. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98(9), 5116-5121 (2001).
29. The R Project for Statistical Computing. www.r-project.org.
30. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2008).
31. Olds EG. A note on the convolution of uniform distributions. Ann. Math. Stat. 23(2), 282-285 (1952).
32. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102(43), 15545-15550 (2005).
33. Meil? M. Comparing clusterings by the variation of information. Learn. Theory Kernel Machines 2777, 173-187 (2003).
34. Meil? M. Comparing clusterings-an information based distance. J. Multivariate Anal. 98(5), 873-895 (2007).
35. Jiang H, Wong WH. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics 24(20), 2395-2396 (2008).
36. Baker ME, Ruggeri B, Sprague LJ et al. Analysis of endocrine disruption in Southern California coastal fish using an aquatic multispecies microarray. Environ. Health Perspect. 117(2), 223-230 (2009).
37. Wilson KD, Li Z, Wagner R et al. Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS ONE 3(7), e2609 (2008).
38. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl Acad. Sci. USA 103(46), 17450-17455 (2006).
39. Augustus AS, Buchanan J, Park TS et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J. Biol. Chem. 281(13), 8716-8723 (2006).
40. Yu X, Burgess SC, Ge H et al. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl Acad. Sci. USA 102(5), 1767-1772 (2005).
41. Fitzpatrick DR, Germain-Lee E, Valle D. Isolation and characterization of rat and human cDNAs encoding a novel putative peroxisomal enoyl-CoA hydratase. Genomics 27(3), 457-466 (1995).
42. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10(6), 238-245 (2000).
43. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85(3), 1093-1129 (2005).
44. Sprenkle AB, Murray SF, Glembotski CC. Involvement of multiple cis elements in basal-and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. Circ. Res. 77(6), 1060-1069 (1995).
45. Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr. Drug Metabol. 9(2), 122-128 (2008).
46. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med. 25(5-6), 495-520 (2004).
47. van der Leij FR, Huijkman NC, Boomsma C, Kuipers JR, Bartelds B. Genomics of the human carnitine acyltransferase genes. Mol. Genet. Metabol. 71(1-2), 139-153 (2000).
48. Rasmussen BB, Holmbäck UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J. Clin. Invest. 110(11), 1687-1693 (2002).
49. van Sligtenhorst I, Ding ZM, Shi ZZ, Read RW, Hansen G, Vogel P. Cardiomyopathy in alpha-kinase 3 (ALPK3)-deficient mice. Vet. Pathol. 49(1), 131-141 (2012).
50. Breckpot J, Tranchevent LC, Thienpont B et al. BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome. Eur. J. Med. Genet. 55(1), 12-16 (2012).
51. Gaussin V, van de Putte T, Mishina Y et al. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc. Natl Acad. Sci. USA 99(5), 2878-2883 (2002).
52. Maillet M, Lynch JM, Sanna B, York AJ, Zheng Y, Molkentin JD. Cdc42 is an antihypertrophic molecular switch in the mouse heart. J. Clin. Invest. 119(10), 3079-3088 (2009).
53. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 125(12), 1551-1562 (2012).
54. Trivedi CM, Cappola TP, Margulies KB, Epstein JA. Homeodomain only protein x is down-regulated in human heart failure. J. Mol. Cell Cardiol. 50(6), 1056-1058 (2011).
55. Loomes KM, Underkoffler LA, Morabito J et al. The expression of Jagged1 in the developing mammalian heart correlates with cardiovascular disease in Alagille syndrome. Hum. Mol. Genet. 8(13), 2443-2449 (1999).
56. Landstrom AP, Weisleder N, Batalden KB et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J. Mol. Cell. Cardiol. 42(6), 1026-1035 (2007).
57. Garbino A, van Oort RJ, Dixit SS, Landstrom AP, Ackerman MJ, Wehrens XH. Molecular evolution of the junctophilin gene family. Physiol. Genomics 37(3), 175-186 (2009).
58. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 89(2), 265-272 (2011).
59. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J. Mol. Cell. Cardiol. 26(3), 279-292 (1994).
60. Miller AD, Tyagi SC. Mutation in collagen gene induces cardiomyopathy in transgenic mice. J. Cell. Biochem. 85(2), 259-267 (2002).
61. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J. Clin. Invest. 117(3), 568-575 (2007).
62. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69(3), 562-573 (2006).
63. Nagase H, Woessner JF. Matrix metalloproteinases. J. Biol. Chem. 274(31), 21491-21494 (1999).
64. Romanic AM, Harrison SM, Bao W et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc. Res. 54(3), 549-558 (2002).
65. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110(5), 625-632 (2002).
66. Reilly MP, Li M, He J et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377(9763), 383-392 (2011).
67. Patel RS, Ye S. ADAMTS7: a promising new therapeutic target in coronary heart disease. Expert Opin. Ther. Targets 17(8), 863-867 (2013).
68. Boesgaard TW, Gjesing AP, Grarup N et al. Variant near ADAMTS9 known to associate with Type 2 diabetes is related to insulin resistance in offspring of Type 2 diabetes patients-EUGENE2 study. PLoS ONE 4(9), e7236 (2009).
69. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123(2), 255-278 (2009).